Rita Morán-Zendejas1, Mayra Delgado-Ramírez1, Jie Xu2,3, Belkis Valdés-Abadía1, Iván A Aréchiga-Figueroa4, Meng Cui3, Aldo A Rodríguez-Menchaca1. 1. Departamento de Fisiología y Biofísica, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico. 2. Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou, China. 3. Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA. 4. CONACyT, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
Abstract
BACKGROUND AND PURPOSE: Aminoglycoside antibiotics are positively charged molecules that are known to inhibit several ion channels. In this study, we have shown that aminoglycosides also inhibit the activity of Kir4.1 channels. Aminoglycosides inhibit Kir4.1 channels by a pore-blocking mechanism, plugging the central vestibule of the channel. EXPERIMENTAL APPROACH: Patch-clamp recordings were made in HEK-293 cells transiently expressing Kir4.1 channels to analyse the effects of gentamicin, neomycin and kanamycin. In silico modelling followed by mutagenesis were realized to identify the residues critical for aminoglycosides binding to Kir4.1. KEY RESULTS: Aminoglycoside antibiotics block Kir4.1 channels in a concentration- and voltage-dependent manner, getting access to the protein from the intracellular side of the plasma membrane. Aminoglycosides block Ki4.1 with a rank order of potency as follows: gentamicin ˃ neomycin ˃ kanamycin. The residues T128 and principally E158, facing the central cavity of Kir4.1, are important structural determinants for aminoglycosides binding to the channel, as determined by our in silico modelling and confirmed by mutagenesis experiments. CONCLUSION AND IMPLICATIONS: Kir4.1 channels are also target of aminoglycoside antibiotics, which could affect potassium transport in several tissues.
BACKGROUND AND PURPOSE:Aminoglycoside antibiotics are positively charged molecules that are known to inhibit several ion channels. In this study, we have shown that aminoglycosides also inhibit the activity of Kir4.1 channels. Aminoglycosides inhibit Kir4.1 channels by a pore-blocking mechanism, plugging the central vestibule of the channel. EXPERIMENTAL APPROACH: Patch-clamp recordings were made in HEK-293 cells transiently expressing Kir4.1 channels to analyse the effects of gentamicin, neomycin and kanamycin. In silico modelling followed by mutagenesis were realized to identify the residues critical for aminoglycosides binding to Kir4.1. KEY RESULTS:Aminoglycoside antibiotics block Kir4.1 channels in a concentration- and voltage-dependent manner, getting access to the protein from the intracellular side of the plasma membrane. Aminoglycosides block Ki4.1 with a rank order of potency as follows: gentamicin ˃ neomycin ˃ kanamycin. The residues T128 and principally E158, facing the central cavity of Kir4.1, are important structural determinants for aminoglycosides binding to the channel, as determined by our in silico modelling and confirmed by mutagenesis experiments. CONCLUSION AND IMPLICATIONS: Kir4.1 channels are also target of aminoglycoside antibiotics, which could affect potassium transport in several tissues.
Authors: M Pichler; Z Wang; C Grabner-Weiss; D Reimer; S Hering; M Grabner; H Glossmann; J Striessnig Journal: Biochemistry Date: 1996-11-19 Impact factor: 3.162
Authors: Detlef Bockenhauer; Sally Feather; Horia C Stanescu; Sascha Bandulik; Anselm A Zdebik; Markus Reichold; Jonathan Tobin; Evelyn Lieberer; Christina Sterner; Guida Landoure; Ruchi Arora; Tony Sirimanna; Dorothy Thompson; J Helen Cross; William van't Hoff; Omar Al Masri; Kjell Tullus; Stella Yeung; Yair Anikster; Enriko Klootwijk; Mike Hubank; Michael J Dillon; Dirk Heitzmann; Mauricio Arcos-Burgos; Mark A Knepper; Angus Dobbie; William A Gahl; Richard Warth; Eamonn Sheridan; Robert Kleta Journal: N Engl J Med Date: 2009-05-07 Impact factor: 91.245
Authors: Iván A Aréchiga-Figueroa; Leticia G Marmolejo-Murillo; Meng Cui; Mayra Delgado-Ramírez; Marcel A G van der Heyden; José A Sánchez-Chapula; Aldo A Rodríguez-Menchaca Journal: Eur J Pharmacol Date: 2017-10-06 Impact factor: 4.432
Authors: Mohammad A K Azad; Julie L M Moreau; Jing Lu; Yan Zhu; Xukai Jiang; Mary Tonta; Rachel Lam; Hasini Wickremasinghe; Jinxin Zhao; Jiping Wang; Harold A Coleman; Luke E Formosa; Tony Velkov; Helena C Parkington; Alexander N Combes; Joseph Rosenbluh; Jian Li Journal: Cell Mol Life Sci Date: 2022-05-15 Impact factor: 9.207